STATİNE BAĞLI RABDOMİYOLİZ: OLGU SUNUMU

Year 2015, Volume: 5 Issue: 2, 75 - 79, 01.06.2015

Tekin Yıldırım , Hüseyin Ede Zeynep Tuğba Özdemir Elif Börekçi

Abstract

Statinler hipelipidemi tedavisinde sıklıkla kullanılan güvenilir ilaçlardır. Statine bağlı rabdo- miyoliz en çok korkulan ve en çok bahsedilen yan etki olmasına rağmen nadiren görülür. Bu yazıda, ciddi klinik sonuçlara yol açabilme potansiyeli nedeniyle, statin ve fibrat türev- lerinin birlikte kullanımına dikkat çekmek amacıyla, statine bağlı gelişen bir rabdomiyoliz olgusunu sunduk.
Anahtar kelimeler: Rabdomiyoliz, Statin, Fibrat
ABSTRACT
Statins are safe drugs used frequently in the treatment of hyperlipidemia. Statin related rhabdomyolysis is the worst and the mostly mentioned side effect of statins but very rarely seen. In this article, to call attention to potentially life-threatening side effects of using combination of statin and fibrate derivatives, we reported a case of rhabdomyolysis developed by statin use.
Keywords: Rhabdomyolysis, Statin, Fibrate

Keywords

Rabdomiyoliz, Statin, Fibrat

References

• Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005;84(6):377-85.
• Haas CE, Magram Y, Mishra A.Rhabdomyolysis and acute renal failure following an ethanol and diphenhidramine overdose. Ann Pharmacother. 2003;37(4):538-42.
• Rodrigez ML, Mora C, Navaro JF.Cerivastatin-induced rhabdomyolisis. Ann Intem Med. 2000;132(7):598.
• Unal A, Torun E, Sipahioglu MH, Tokgoz B, Kaya MG, Oymak O, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Inter Med. 2008;47(11):1017-9.
• Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmaco epidemiol Drug Saf. 2007;16(3):352-8.
• Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med. 2005;142(11):949-50.
• Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate- derivative combination and occult hypothyroidism. Clin Nephrol. 2005;64(5):391-3.
• Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-loweringdrugs. JAMA. 2004;292(21):2585-90.
• Antos KA, Williams CD, Baker SK, Philiph PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400-9.
• Polderman KH. Acute renal failure and rhabdomyolysis. Int J Artif Organs. 2004;27(12):1030-3.
• A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137(7):617-8.
• Sathasivam S, Lecky B.Statin induced myopathy. BMJ. 2008;337:a2286.
• Sathasivam S. Statin induced myotoxicity. Eur J InternMed. 2012;23(4):317-24.
• Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicitiy; pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145(1):99-110.
• Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cell stolovastatin and pravastatin. J Mol Cell Cardiol. 1995;27(10):2397-402.
• Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, et al.The effect of simvastatin treatment on natural antioxidants in low density lipoproteins and high- energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77(10):851-4.
• Rosenson RS.Current overview of statin induced myopathy. Am J Med 2004;116(6):408-16.
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri-can College of Cardiology; American HeartAssociation; NationalHeart, Lungand Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337-41.
• Amend KL, Landon J, Thyagarajan V, NiemcrykS, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrat euse in an insured US population. Ann Pharmacother. 2011;45(10):1230-9.
• Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstol K, et al.Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012;32(4):281-91.
• Davidson MH, Armani A, Mc Kenney JM, Jacobson TA.Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C-18C.
• Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007;19(1):67
• Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12):1169